Objective: Identification of frailty by clinical criteria is often delayed to the advanced stage. A reliable biomarker to identify frailty or its risk does not currently exist. We aimed to determine the association between serum cystatin C and frailty in subjects without renal dysfunction.
| INTRODUCTION
continues. [3] [4] [5] [6] [7] The association between kidney function and frailty with serum creatinine was studied in a Cardiovascular Health Study cohort. 2 The
Osteoporosis in Men Study group showed that higher cystatin C was better associated with frailty, using frailty phenotype criteria, than creatinine 8 and was also associated with poorer performance on physical function. This association was present even at normal renal function, independent of several potential confounders and biological mediators. However, this study was done only in a male cohort. Odden et al 9 showed that lifestyle, chronic health conditions, inflammation, and physical inactivity only moderately attenuate the relation between cystatin C and physical function.
Cystatin C is a 122 amino acid, 13-kDa protein belonging to the family of cysteine proteases inhibitors. It is encoded by the CST3
gene, produced by all nucleated cells, and found in all body fluids.
Free filtration in glomerulus and maximal reabsorption in proximal tubule of the kidney has made this molecule ideal for calculation of estimated glomerular filtration rate (eGFR) 10 and is better than creatinine-based eGFR estimation. 11 Chronic kidney disease (CKD) estimated by eGFR (cystatin) was associated with higher chances of incident mobility disability and greater decline in gait speed, highlighting the loss of physical independence in elderly CKD patients. 12 Dalrymple et al 13 found that lower eGFR (cystatin) was associated with a higher risk of prevalent and incident frailty, whereas lower eGFR (creatinine) was not. Yaffe et al 14 found that in CKD patients, Values marked with * are statistically significant.
higher cystatin C was associated with poor cognitive function. A study from the United States showed that higher cystatin C level was associated with unsuccessful aging, even when the renal function was normal. 15 In this study, we used cumulative deficit criteria to define frailty to look at the association of cystatin C with frailty in both sexes irrespective of renal function.
| ME TH ODS
A cross-sectional observational study was done in the Geriatric made to identify the cutoff point of cystatin C in the detection of frailty. Based on this cutoff point, the group was divided into two and univariate and multivariate analysis were done for frailty and higher cystatin C with clinically and/or statistically significant variables. The result was considered significant at the 5% level of significance (P < 0.05).
| Statistical analysis

| RESULTS
The mean age of the study sample was 76.32 years with 72 (57.6%) male and 53 (42.4%) female participants. Seventy-three subjects were frail and 52 were non-frail. Mean cystatin C levels in the frail and non-frail groups were 1.28 mg/L (±0.39) and 1.12 mg/L (±0.27), respectively, and the difference was significant (P = 0.012). Table 1 shows values of cystatin C with other variables. Mean levels of cystatin C in frail male (1.32 ± 0.38 mg/L) and female (1.25 ± 0.40 mg/L) participants were significantly higher than those in non-frail male (1.15 ± 0.29 mg/L) and female (1.00 ± 0.18 mg/L)
participants. There was no significant difference between serum cystatin C values when compared between sexes. The mean value of cystatin C increased with age but no significant differences existed between different age groups (<75 and ≥75 years).
The mean cystatin C value was significantly higher in frail subjects with higher body mass index (BMI; >23 kg/m 2 ) compared to non-frail subjects in the same group. A significant difference was not seen in the BMI ≤23 group. In subjects with hypertension, frail subjects had significantly higher cystatin C levels (1.39 ± 0.42 mg/L) than non-frail subjects (1.10 ± 0.33 mg/L). A significant difference was not seen in the group without hypertension. In subjects with diabetes, coronary Cystatin C <1.12 1 P = 0.049* 1 P = 0.037* Study group, found that higher cystatin C was associated with greater odds of frailty; that study had only male subjects and used frailty phenotype criteria. In our study, subjects from both sexes were included and no significant difference with sex was seen. In subjects with hypertension and cognitive impairment, there was a significant increase of mean cystatin C values in the frail group. In other comorbidities, there was no significant difference in the cystatin C values.
The exact role of cystatin C in the pathophysiology of frailty is not known. Its roles in the inhibition of endogenous or exogenous cysteine peptidases (including muscle cells) and in the modulation of the immune system in aging cells may have links with frailty. 16 However, higher serum cystatin C levels seem to be associated with an increased risk of frailty. This could be tested in larger prospective studies to identify the predictability of incident frailty. A raised serum cystatin C level with other biomarkers may help in the early identification of frailty in older adults during the preclinical stage.
The strength of this study was using a newer serum molecule to identify an association with frailty status in older adults. A standardized methodology involving nephelometry was used to determine serum levels of cystatin C. The limitations of the study include the small sample size, the hospital-based population, and the cross-sectional nature of the study. However, this study will help future longitudinal cohort research to study this molecule in relation with frailty.
In summary, raised serum cystatin C was associated with higher risk of being frail. A cystatin C cutoff of 1.12 mg/L was proposed to identify frail subjects with about 60% sensitivity and 58% specificity.
Cystatin C has a potential role in identifying frail subjects early and more research is needed.
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